Management of highly emetogenic chemotherapy

Current Opinion in Oncology

Volumn 24, Issue 4, 2012, Pages 371-375

  Warr, David ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

antiemetic guidelines; aprepitant; chemotherapy; highly emetogenic; palonosetron

Indexed keywords

ANTIEMETIC AGENT; APREPITANT; BLEOMYCIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; DACARBAZINE; DEXAMETHASONE; DOLASETRON MESILATE; DOXORUBICIN; FOSAPREPITANT; GRANISETRON; OLANZAPINE; PALONOSETRON; PREDNISONE; STREPTOZOCIN; VINCRISTINE;

ANTIEMETIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; DISEASE CONTROL; DROWSINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TOLERABILITY; HODGKIN DISEASE; HUMAN; LUNG CANCER; NAUSEA; NAUSEA AND VOMITING; PATIENT SATISFACTION; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SINGLE DRUG DOSE; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; VOMITING;

EID: 84862154706     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328352f6fb     Document Type: Review

References (28)

1. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American society of clinical oncology clinical practice guideline update. J Clin Oncol 2011; 29:4189-4198.
2. Roila F, Herrstedt J, Aapro M, et al. Guideline update for mascc and esmo in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the perugia consensus conference. Ann Oncol 2010; 21 (Suppl 5):v232-v243.
3. Antiemesis: 2011. http://www.nccn.org/professionals/physician-gls/pdf/ antiemesis.pdf. [Accessed 25 January 2012]
4. Warr DG, Grunberg SM, Gralla RJ, et al. The oral nk(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from two randomized, double-blind, placebo controlled trials. Eur J Cancer 2005; 41:1278-1285. (Pubitemid 40813003)
5. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005; 23:2822-2830. (Pubitemid 46179473)
6. Di Renzo N, Montanini A, Mannina D, et al. Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive nonhodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the gruppo italiano per lo studio dei linfomi (gisl). Support Care Cancer 2011; 19:1505-1510.
7. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 2011; 9:188-195.
8. Tan L, Liu J, Liu X, et al. Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 2009; 28:131.
9. Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 h after chemotherapy to prevent delayed emesis? Systematic reevaluation of clinical evidence and drug cost implications. J Clin Oncol 2005; 23:1289-1294. (Pubitemid 46202287)
10. Likun Z, Xiang J, Yi B, et al. A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults. Oncologist 2011; 16:207-216.
11. Gonullu G, Demircan S, Demirag MK, et al. Electrocardiographic findings of palonosetron in cancer patients. Support Care Cancer 2011. [Epub ahead of print]
12. Yavas C, Dogan U, Yavas G, et al. Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study. Support Care Cancer 2011. [Epub ahead of print]
13. Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol-EASE. J Clin Oncol 2011; 29:1495-1501.
14. Marbury TC, Ngo PL, Shadle CR, et al. Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150mg fosaprepitant in healthy adult subjects. J Clin Pharmacol 2011; 51:1712-1720.
15. Aprepitant and fosaprepitant time-on-target pet (positron emission tomography) study (0869-183): US National Institutes of Health, 2011. http://www.clinicaltrials.gov/ct2/show/NCT01111851?term/fosaprepitant rank/3. [Accessed 25 January 2012]
16. Einhorn LH, Grunberg SM, Rapoport B, et al. Antiemetic therapy for multipleday chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 2011; 19 (Suppl 1):S1-S4.
17. Jordan K, Jahn F, Jahn P, et al. The nk-1 receptor-antagonist aprepitant in highdose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide)-efficacy and safety of a triple antiemetic combination. Bone Marrow Transplant 2011; 46:784-789.
18. Patrick Stiff MF-G, Karen Kiley, Nancy Porter, et al. Tulio Rodriguez Aprepitant vs. Placebo plus oral ondansetron and dexamethasone for the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to hematopoietic stem cell transplantation: a prospective, randomized double-blind phase III trial. ASH Annual Meeting 2009; 114:Abs2267.
19. Paul B, Trovato JA, Thompson J, et al. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support. J Oncol Pharm Pract 2010; 16:45-51.
20. Pielichowski W, Barzal J, Gawronski K, et al. A triple-drug combination to prevent nausea and vomiting following beam chemotherapy before autologous hematopoietic stem cell transplantation. Transplant Proc 2011; 43:3107-3110.
21. Walko CM, Combest AJ, Spasojevic I, et al. The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol 2012. [Epub ahead of print]
22. Bubalo JS, Cherala G, McCune JS, et al. Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation. J Clin Pharmacol 2011. [Epub ahead of print]
23. Aapro MS, Walko CM. Aprepitant: drug-drug interactions in perspective. Ann Oncol 2010; 21:2316-2323.
24. Hatoum HT, Lin SJ, Buchner D, Cox D. Comparative clinical effectiveness of various 5-HT(3) RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice. Support Care Cancer 2011. [Epub ahead of print]
25. Molassiotis A, Brearley SG, Stamataki Z. Use of antiemetics in the management of chemotherapy-related nausea and vomiting in current UK practice. Support Care Cancer 2011; 19:949-956.
26. Aapro AMM, Dicato M, Gascon P, et al. Effect of guideline consistent chemotherapy prophylaxis (gccp) on chemotherapy-induced nausea and vomiting (cinv): the Pan European Emesis Registry (PEER). Support Care Cancer 2011; 19 (Suppl 2):S186.
27. Burmeister H, Aebi S, Studer C, et al. Adherence to esmo clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Support Care Cancer 2012; 20:141-147.
28. Brames JPMJ, Yu M, Johnston EL, et al. Phase III, double-blind, placebocontrolled, crossover study evaluating a 5-HT3 antagonist plus dexamethasone with or without aprepitant in patients with germ cell tumor receiving 5-day cisplatin combination chemotherapy: a hoosier oncology group (hog) study. J Clin Oncol 2011; 29:abstr9013.